TARA
Companies
NASDAQ
Protara Therapeutics Inc.
Health Care
$2.98
-$2.22 (-42.05%)
Price Chart
Overview
About TARA
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Market Cap
$55.0M
Volume
657.6K
Avg. Volume
729.1K
P/E Ratio
-1.171875
Dividend Yield
0.00%
Employees
30.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.31
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, TARA shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$55.0M
Volume657.6K
P/E Ratio-1.17
Dividend Yield0.00%
Important Dates
Next Dividend
January 10, 2020Next Earnings
March 5, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025